Pulmonology
Starting from
$500
Up to $5,000 depending on centre
Typical duration
7–21 days
Including pre-operative work-up
Partner hospitals
1
Vetted for outcome data & accreditation
Content reviewed for medical accuracy by: Dr. Rodina Ainasoa · Medical Content Writer & Health Communications
Advanced management of chronic obstructive pulmonary disease and severe asthma through optimised pharmacotherapy, structured pulmonary rehabilitation, and minimally invasive bronchoscopic lung volume reduction — offering improved quality of life when standard inhalers have failed. International patients benefit from specialist pulmonologist consultations and state-of-the-art lung function laboratories at affordable prices.
Your case is matched to a centre on the basis of clinical outcome data, not marketing. We coordinate every step — from pre-operative work-up to post-treatment follow-up — with a dedicated care coordinator.
COPD & Asthma Management
Coordinated from
or message us on WhatsApp
No commitment required. Your data is never shared with third parties.
COPD and asthma are managed with a stepwise approach. Most patients are controlled on standard inhaled therapy, but a minority with severe, poorly controlled asthma may be candidates for add-on biologic therapy. Here is how the two approaches compare.
| Parameter | Standard Inhaled Therapy | Add-On Biologic Therapy |
|---|---|---|
| What it does | Inhaled bronchodilators (LABA/LAMA) and, where indicated, inhaled corticosteroids open the airways and reduce inflammation on a daily maintenance basis, per GOLD and GINA. | An injectable monoclonal antibody (e.g. anti-IgE or anti-IL5/IL5R/IL4) targets a specific inflammatory pathway, added on top of — not instead of — optimised inhaled therapy. |
| Who it is for | The first-line approach for essentially all patients with COPD or asthma, per GOLD and GINA stepwise treatment guidance. | Reserved for severe, difficult-to-treat asthma with ongoing exacerbations or poor symptom control despite high-dose inhaled therapy, and only after treatment has been optimised, per GINA. |
| How it is started | Prescribed and titrated by a pulmonologist based on spirometry results, symptom burden, and exacerbation history. | Requires confirmation of eligible biomarkers (such as blood eosinophil count or FeNO, measured on more than one occasion) before a specialist initiates therapy, per GINA. |
| Administration | Self-administered daily or as-needed via inhaler, at home. | Given by injection, typically every two to eight weeks depending on the specific biologic, usually in a clinical setting at least initially. |
| Goal | Control day-to-day symptoms and reduce exacerbation risk as the foundation of long-term management. | Further reduce exacerbations and oral corticosteroid use in patients whose disease remains uncontrolled on standard therapy alone — not a replacement for inhaled treatment. |
COPD and asthma are chronic conditions, so 'treatment' means an ongoing management process rather than a single procedure. The steps below outline a typical pathway; your pulmonologist will tailor the plan to your diagnosis and severity.
Diagnostic workup and spirometry
Lung function is assessed with spirometry to confirm the diagnosis and measure severity, alongside a review of symptoms, triggers, exacerbation history, and — for COPD — smoking status, per GOLD and GINA.
Treatment plan initiation
Your pulmonologist starts you on the appropriate stepwise inhaled therapy (bronchodilators, with or without inhaled corticosteroids) and, for COPD, confirms a smoking-cessation and pulmonary rehabilitation plan where relevant.
Monitoring and titration
Response to therapy is reviewed at follow-up visits, with inhaler technique, adherence, and dosing adjusted based on symptom control and repeat lung function testing.
Escalation if needed
If symptoms or exacerbations persist despite optimised inhaled therapy, your specialist evaluates whether escalation is appropriate — for severe asthma, biomarker testing for biologic eligibility; for selected COPD or asthma cases, referral for bronchoscopic options such as bronchoscopic lung volume reduction or bronchial thermoplasty.
Initial response to therapy is assessed; your pulmonologist checks whether symptoms and inhaler technique have improved and adjusts the regimen if not.
A more complete assessment of symptom control and lung function is typically carried out, guiding any step-up or step-down in therapy per GOLD and GINA review cycles.
For patients started on biologic therapy, response is formally reviewed at around four months and again by twelve months to decide whether to continue, per GINA guidance; COPD patients on pulmonary rehabilitation typically complete their structured programme within this window.
Because COPD and severe asthma are chronic conditions, monitoring, medication review, and trigger or smoking-cessation support continue indefinitely, with periodic specialist review and prompt attention to any worsening symptoms.
Source: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 report; Global Initiative for Asthma (GINA) 2024/2025 strategy reports. Individual management plans vary and are guided by your treating pulmonologist.
Known Risks & Limitations
Source: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 report; Global Initiative for Asthma (GINA) 2024/2025 strategy reports; Mayo Clinic; Cleveland Clinic. No treatment plan eliminates risk; your treating pulmonologist will review your individual case.
Remote case review
Share your spirometry results, imaging, symptom history, and current medications with our coordination team, who forward your case for an initial pulmonology review of suitability for management or intervention abroad.
Specialist and centre matching
We match you with an accredited pulmonology centre experienced in COPD and severe asthma management, including biologic therapy initiation or bronchoscopic options where clinically appropriate.
Cost estimate and travel planning
Once your case is reviewed, we issue a consolidated cost estimate covering consultations, diagnostics, and your initial treatment plan, and help plan a trip length matched to whether your care is a single evaluation, a procedure, or the start of ongoing therapy.
Treatment initiation and monitoring
You attend your consultations and initial treatment — whether medication optimisation, biologic initiation, or a bronchoscopic procedure — with inpatient or outpatient monitoring as appropriate before you are cleared to travel home.
Follow-up and continuity of care
Before you depart, your treatment records and management plan are shared with your home-country pulmonologist or physician so they can continue monitoring and ongoing care, since COPD and severe asthma require lifelong follow-up.
Average coordinated costs across our partner centres. Final pricing depends on clinical complexity and chosen hospital.
| Country | Avg. cost | vs. cheapest |
|---|---|---|
🇮🇳 India New Delhi · Chennai · Bengaluru · Hyderabad · Mumbai · Kochi | $1,000 | —chevron_right |
🇹🇷 Turkey Istanbul | $2,500 | +150%chevron_right |
Costs are indicative estimates and vary by procedure specifics, hospital, and clinical complexity. Request a personalised estimate for your specific case.
Faridabad, India
Asia's largest private hospital — 2,600 beds, 64 operation theatres, 81 specialties on a 130-acre campus in Delhi NCR. NABH & NABL accredited. Centres of excellence in oncology, cardiac surgery, BMT, organ transplantation, neurosciences, and IVF.
800+
Specialists
2,600+
Beds
BLVR with endobronchial valves is suitable for patients with severe emphysema (COPD GOLD stage III-IV) who have significant hyperinflation, are non-responsive to maximum inhaler therapy, and have no significant collateral ventilation in the target lobe. Eligibility is confirmed through a CT scan with fissure analysis and a bronchoscopic Chartis assessment. Your pulmonologist will review your existing scans and lung function reports remotely before travel to confirm suitability.
No fees. No commitment.
We are compensated by our partner hospitals — never by patients. You get independent clinical matching, cost transparency, and end-to-end coordination at no cost to you.
